Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy Subjects

In brief

The purpose of this study is to assess the effect of LX4211 and the comparator drug canagliflozin on intestinal glucose absorption and metabolism after a single dose in healthy subjects in comparison to placebo.

Key facts

Study ID

NCT01916863

Run by

Lexicon Pharmaceuticals

People needed

25

Starts

2013-08-01

Last updated by the study team

2013-10-30

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult subjects ≥18 to ≤55 years of age
• Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm
• Body mass index (BMI) ≥18 and ≤35 kg/sq m
• Willing and able to provide written informed consent

You may not qualify if…

• Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing
• Use of any investigational agent or study treatment within 30 days of Day -1
• Use of any protein or antibody-based therapeutic agents within 3 months of Screening
• Prior exposure to LX4211 or canagliflozin
• Daily use of >5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study
• History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption
• History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying
• History of any major surgery within 6 months prior to Screening
• History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation
• History of renal disease or significantly abnormal kidney function tests
• History of hepatic disease or significantly abnormal liver function tests
• History of any active infection within 30 days prior to Day -1
• History of alcohol or substance abuse within 2 years prior to Day 1
• History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2
• Donation or loss of >500 mL of blood or blood product within 56 days of Day -1
• positive pregnancy test at Screening or Day -1
• Positive urine screen for drugs of abuse at Screening or Day -1
• Positive breath test for alcohol at Screening or Day -1
• Inability or difficulty swallowing whole tablets
• Unable or unwilling to communicate or cooperate with the Investigator

Where it is running

• Lexicon Investigational Site — Chula Vista, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.